Filing Details

Accession Number:
0001140361-15-029579
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-08-03 20:43:48
Reporting Period:
2015-07-30
Filing Date:
2015-08-03
Accepted Time:
2015-08-03 20:43:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1416792 Relypsa Inc RLYP Pharmaceutical Preparations (2834) 260893742
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1477384 A John Orwin C/O Relypsa, Inc.
100 Cardinal Way
Redwood City CA 94063
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-07-30 20,000 $7.40 50,000 No 4 M Direct
Common Stock Disposition 2015-07-30 19,800 $33.57 30,200 No 4 S Direct
Common Stock Disposition 2015-07-30 200 $34.11 30,000 No 4 S Direct
Common Stock Acquisiton 2015-07-31 5,000 $7.40 35,000 No 4 M Direct
Common Stock Disposition 2015-07-31 9,800 $33.51 25,200 No 4 S Direct
Common Stock Disposition 2015-07-31 200 $34.14 25,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2015-07-30 20,000 $0.00 20,000 $7.40
Common Stock Stock Option (right to buy) Disposition 2015-07-31 5,000 $0.00 5,000 $7.40
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
782,877 2023-07-23 No 4 M Direct
777,877 2023-07-23 No 4 M Direct
Footnotes
  1. Includes 20,000 restricted stock units.
  2. The sales reported in this Form 4 were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
  3. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $33.04 to $34.0241, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  4. The shares subject to the option are early exercisable. 25% of the shares subject to the option vest on the first anniversary measured from June 17, 2013 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.
  5. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $33.14 to $34.02, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.